Figure 4.

Protection from lung tumors in CD1d^−/− mice does not confer protection against s.c. tumors. (A and B) WT or CD1d^−/− mice were challenged with CT26 cells s.c. and/or i.v on the same day. S.c. tumors were measured until mice had to be euthanized due to lung tumors. Lungs from mice receiving i.v. tumor challenge were stained and tumors were enumerated. (C) Mice were challenged with CT26 cells i.v. One week later, mice were challenged with CT26 cells s.c and s.c. tumor growth monitored. (D and E) CD1d^−/− mice were challenged with CT26 cells i.v. One week later, T cells from these mice were transferred into RAG1^−/− mice. One day after T cell transfer, mice were challenged with CT26 s.c. (D) or i.v. (E). S.c. growth was monitored three times a week. Data are expressed as mean ± standard deviation (B-D, n = 5). Lungs from mice receiving i.v. tumor challenge were stained and tumors were enumerated on day 22. The numbers of lung metastases are expressed as mean ± standard deviation (A, n = 5 E, n = 15 for RAG1^−/− group and n = 16 for RAG1^−/− + immune CD1d^−/− T cells group). Representative data from at least two independent experiments are shown. Statistically significant differences (**p<0.01,****p<0.0001) were determined by the Mann-Whitney test.